Susan Altschuller Joins Dragonfly Therapeutics As The New CFO

Dragonfly Therapeutics Inc. has bolstered its executive leadership team by appointing Dr. Susan Altschuller as its new Chief Financial Officer. With over 20 years of extensive experience in strategic and financial leadership roles within top pharmaceutical and biotechnology firms, Altschuller brings a wealth of expertise to the position. Most recently, she was the CFO of Cerevel Therapeutics, where she played a key role in developing therapies for neuroscience disorders until the company was acquired by AbbVie.

Prior to her tenure at Cerevel, Altschuller served as CFO at ImmunoGen, where she facilitated the oncology company’s inaugural commercial launch. Her career also includes significant roles at Alexion, where she was vice president and head of investor relations, as well as head of enterprise finance. Additionally, she held the position of head of investor relations at Bioverativ, a hemophilia-focused spin-off from Biogen, and worked in various finance roles at Biogen, including as a senior consultant for the Frankel Group.

Dr. Altschuller earned her BSE in Biomedical Engineering with Honors from Tulane University, followed by a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology and an MBA from the MIT Sloan School of Management. She has also contributed her expertise as the audit chair on the Board of Directors for Vestaron Corporation and Mural Oncology, and is a founding Board member of the HNRNP Family Foundation.

Bill Haney, Co-Founder and CEO of Dragonfly Therapeutics, said that, "We are delighted that Susan has joined Dragonfly," said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. Her leadership in growing successful biopharma companies comes at an exciting time as Dragonfly expands its clinical pipeline in autoimmune disease, oncology, and neuro-inflammatory disease. Susan's powerful combination of financial, clinical and development experience will help drive our mission to help patients by inventing and commercializing leading immune-engaging therapeutics.”